Literature DB >> 8650716

Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.

A Lindgren1, C Lindoff, B Norrving, B Astedt, B B Johansson.   

Abstract

BACKGROUND AND
PURPOSE: Abnormal endogenous fibrinolytic activity may be a risk factor for stroke. Since the possible variation of tissue-type plasminogen activator (TPA) antigen and plasminogen activator inhibitor-1 (PAI-1) antigen concentrations over time after stroke has been rarely studied, it was examined in plasma from stroke patients in the acute and convalescent phases of the disease and in a control group.
METHODS: Plasma concentrations of TPA and PAI-1 were determined in 135 stroke patients and in 77 control subjects. All but 4 patients were examined within 7 days after stroke onset, and 32 patients and 18 control subjects were reexamined 2 to 4 years later.
RESULTS: In the acute phase, stroke patients had significantly higher TPA (median, 10 micrograms/L) and PAI-1 (median, 14 micrograms/L) antigen concentrations, compared with control subjects (median values, 6 micrograms/L [P = .0001] and 8 micrograms/L [P < .01], respectively); TPA levels were higher in both the cerebral infarction (n = 122) and cerebral hemorrhage (n = 12) subgroups, whereas PAI-1 levels were higher in the cerebral infarction subgroup only. Stepwise logistic regression analysis (with correction for age, sex, history of hypertension, diabetes mellitus, and heart disease) showed TPA antigen level to be an independent discriminator between the cerebral infarction subgroup and control subjects (P = .0001), whereas the corresponding difference for PAI-1 antigen levels just failed to reach significance (P = .05). TPA antigen levels were correlated with concentrations of serum cholesterol (Spearman's rho = 0.15; P < .05), serum triglyceride (rho = 0.33; P = .0001), and plasma homocysteine (rho = 0.19; P < .01). PAI-1 antigen levels were correlated with serum triglyceride levels only (rho = 0.41; P = .0001). At reexamination after 2 to 4 years, neither TPA nor PAI-1 levels had changed significantly from the baseline values.
CONCLUSIONS: In stroke patients, high TPA antigen concentrations may indicate an activation of the fibrinolytic system or may be due to a delayed clearance of TPA complexed with inhibitors. High PAI-1 antigen concentrations in patients with cerebral infarction represent increased fibrinolytic inhibition. The findings in this longitudinal study suggest that TPA and PAI-1 antigen concentrations both differ little between the acute and convalescent phases after stroke.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8650716     DOI: 10.1161/01.str.27.6.1066

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  22 in total

Review 1.  The vascular basement membrane in the healthy and pathological brain.

Authors:  Maj S Thomsen; Lisa J Routhe; Torben Moos
Journal:  J Cereb Blood Flow Metab       Date:  2017-07-28       Impact factor: 6.200

Review 2.  The effect of exercise on coagulation and fibrinolysis factors in patients with peripheral arterial disease.

Authors:  Nikolaos Patelis; Georgios Karaolanis; Georgios N Kouvelos; Collin Hart; Sean Metheiken
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-20

3.  Systemic augmentation of alphaB-crystallin provides therapeutic benefit twelve hours post-stroke onset via immune modulation.

Authors:  Ahmet Arac; Sara E Brownell; Jonathan B Rothbard; Charlene Chen; Rose M Ko; Marta P Pereira; Gregory W Albers; Lawrence Steinman; Gary K Steinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-26       Impact factor: 11.205

Review 4.  Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease.

Authors:  K Huber
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

Review 5.  Can the time window for administration of thrombolytics in stroke be increased?

Authors:  Geoffrey A Donnan; David W Howells; Romesh Markus; Danilo Toni; Stephen M Davis
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

6.  Plasma fibrinolysis inhibitor levels in acute stroke patients with thrombolysis failure.

Authors:  Seo Hyun Kim; Sang Won Han; Eun Hee Kim; Dong Joon Kim; Kyung Yul Lee; Dong Ik Kim; Ji Hoe Heo
Journal:  J Clin Neurol       Date:  2005-10-20       Impact factor: 3.077

Review 7.  Can we use statins to prevent stroke in Fabry disease?

Authors:  J M Politei
Journal:  J Inherit Metab Dis       Date:  2009-06-02       Impact factor: 4.982

8.  Comprehensive analysis of glomerular mRNA expression of pro- and antithrombotic genes in atypical haemolytic-uremic syndrome (aHUS).

Authors:  Friedrich Modde; Putri Andina Agustian; Juliane Wittig; Maximilian Ernst Dämmrich; Vinzent Forstmeier; Udo Vester; Thurid Ahlenstiel; Kerstin Froede; Ulrich Budde; Anne-Margret Wingen; Anke Schwarz; Svjetlana Lovric; Jan Thomas Kielstein; Carsten Bergmann; Nadine Bachmann; Mato Nagel; Hans Heinrich Kreipe; Verena Bröcker; Clemens Luitpold Bockmeyer; Jan Ulrich Becker
Journal:  Virchows Arch       Date:  2013-03-09       Impact factor: 4.064

9.  Hemostatic factors and subclinical brain infarction in a community-based sample: the ARIC study.

Authors:  R F Gottesman; C Cummiskey; L Chambless; K K Wu; N Aleksic; A R Folsom; A R Sharrett
Journal:  Cerebrovasc Dis       Date:  2009-10-16       Impact factor: 2.762

10.  Embolic middle cerebral artery occlusion model using thrombin and fibrinogen composed clots in rat.

Authors:  Ming Ren; Zi-Jing Lin; Hai Qian; Gourav Roy Choudhury; Ran Liu; Hanli Liu; Shao-Hua Yang
Journal:  J Neurosci Methods       Date:  2012-09-14       Impact factor: 2.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.